Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Panaxia Labs Israel Ltd
  6. News
  7. Summary
    PNAX   IL0011043630

PANAXIA LABS ISRAEL LTD

(PNAX)
  Report
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Panaxia Labs Israel Ltd. and Neuraxpharm Expands Strategic Collaboration to Poland

08/19/2021 | 05:40am EST

Panaxia Labs Israel Ltd. and its partner, Neuraxpharm, announced expanding their strategic collaboration into the Polish market. The companies signed an exclusive agreement to the manufacture, commercialization, and distribution of Panaxia's advanced medical cannabis-based products in Poland, a large market with significant growth potential in European and global standards, after a former successful collaboration in Germany and France. The commercial collaboration between both companies will be executed in a similar model to their cooperation in Germany: Panaxia will be responsible for the manufacturing of the products, developed under strict clinical standards. The products will include premium oils, and inhaled extracts, complying with European standards (EU-GMP). Neuraxpharm will be in charge of the branding, distribution and marketing of the products to doctors, patients and pharmacies in Poland. This agreement strengthens the establishment of Panaxia and Neuraxpharm as key players in the European medical cannabis market and is expected to expand to other countries.


ę S&P Capital IQ 2021
All news about PANAXIA LABS ISRAEL LTD
08/31Panaxia Labs Israel Ltd Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
08/19Panaxia Labs Israel Ltd. and Neuraxpharm Expands Strategic Collaboration to Poland
CI
08/09IM Cannabis Corp.
AQ
04/30IMC Holdings Ltd. agreed to acquire Israel's Largest Retail and Online Pharmacy Busines..
CI
04/12Panaxia Labs Israel Ltd Provides Revenue Guidance for the First Quarter of 2021
CI
04/05Panaxia Labs Israel Ltd Reports Earnings Results for the Fourth Quarter and Year 2020
CI
02/03Government of Cyprus Selects Panaxia Labs Israel Ltd. to Supply Premium Oils
CI
01/28Neuraxpharm France and Panaxia Labs Select the Participation in A Pilot Program for the..
CI
2020Panaxia Labs Israel Ltd Reports Revenue Results for the Third Quarter and Nine Months o..
CI
2020Panaxia Labs Israel Ltd. and Neuraxpharm to Receive A Marketing Permit for Medical Cann..
CI
More news
Financials
Sales 2019 16,7 M 5,28 M 5,28 M
Net income 2019 -81,3 M -25,7 M -25,7 M
Net cash 2019 0,60 M 0,19 M 0,19 M
P/E ratio 2019 -2,85x
Yield 2019 -
Capitalization 170 M 53,4 M 53,8 M
EV / Sales 2018 -
EV / Sales 2019 2,77x
Nbr of Employees -
Free-Float 33,5%
Chart PANAXIA LABS ISRAEL LTD
Duration : Period :
Panaxia Labs Israel Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Dadi Segal Chief Executive Officer & Director
Gil Benyamini Chief Financial Officer
Jonathan B. Kolber Chairman
Eran Goldberg Chief Technology Officer
Tamar Hinenzon Meiri Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
PANAXIA LABS ISRAEL LTD-56.20%53
CINTAS CORPORATION21.17%44 288
TELEPERFORMANCE SE31.59%23 727
BUREAU VERITAS SA29.83%14 444
INTERTEK GROUP PLC-3.47%11 695
EDENRED SE-12.91%11 395